Receive our newsletter – data, insights and analysis delivered to you
  1. Deals
December 10, 2021updated 07 Jan 2022 8:30am

BD acquires surgical sealant films developer Tissuemed

The acquisition will add the Tissuemed surgical sealant to BD’s suite of biosurgery products.

Becton, Dickinson and Company (BD) has acquired self-adhesive surgical sealant films developer Tissuemed for an undisclosed amount.

Tissuemed’s sealant technology, Tissuepatch, binds to tissues to prevent leaks from surgical incisions and can be used to control internal bleeding.

With a thin, flexible and transparent composition, the technology helps clinicians to seal sutured or stapled tissues against leakage of air, blood and other fluids, including cerebrospinal fluid (CSF), after surgical procedures.

It is said to be ideally suited for a range of surgical sealant applications.

BD stated that the acquisition of Tissuemed expands its offerings for surgeons outside the US and across the globe.

It also complements the company’s core portfolio by adding Tissuemed’s surgical sealant to its suite of biosurgery products, which are already being used in the operating room.

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

BD surgery president Kevin Kelly said: “This advanced sealant serves as a strategic complement to the BD products used in the operating room today, providing us with the opportunity to equip surgeons with a more robust, highly-integrated portfolio of surgical solutions.

“Integrating Tissuepatch into our business aligns with our commitment to continuously innovate in our core portfolio to help support minimally invasive surgeries.”

With significant growth plans for the next five to ten years, the company plans to use its clinical expertise to advance the sealant technology category.

In October, BD partnered with the US Biomedical Advanced Research and Development Authority (BARDA) to develop a range of Covid-19 combination diagnostic tests.

As part of the partnership, BARDA agreed to provide initial funding of $24.7m to BD, which could be extended up to $40.3m.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU